Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.53 |
| ▸ | PPARG | P37231 | 1/20 | 0.53 |
| ▸ | LIPE | Q05469 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | DHPS | P49366 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29709477 | 1.00 | RAB9A (0.54) | RAB9ANPC1SMN1; SMN2GAAMAPK1 | |
| SCHEMBL2997564 | 0.92 | LIPE (0.49) | RAB9ANPC1SMN1; SMN2GAAMAPK1 | |
| SCHEMBL15607795 | 0.89 | LIPE (0.61) | RAB9ANPC1SMN1; SMN2GAAMAPK1 | |
| SCHEMBL13893964 | 0.89 | MAPT (0.49) | RAB9ANPC1SMN1; SMN2LIPEL3MBTL1 | |
| SCHEMBL16333710 | 0.88 | LIPE (0.46) | RAB9ANPC1SMN1; SMN2GAAMAPK1 | |
| SCHEMBL13765533 | 0.88 | LIPE (0.51) | RAB9ANPC1SMN1; SMN2GAAMAPK1 | |
| SCHEMBL26109550 | 0.88 | POLB (0.50) | RAB9ANPC1MAPK1NR1H4PPARG | |
| SCHEMBL30586951 | 0.87 | MEN1 (0.51) | SMN1; SMN2LIPEALDH1A1MAPTMEN1 | |
| SCHEMBL124355 | 0.87 | MEN1 (0.51) | SMN1; SMN2LIPEALDH1A1MAPTMEN1 | |
| SCHEMBL2992272 | 0.87 | LIPE (0.51) | RAB9ANPC1SMN1; SMN2GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023183652-A1 | DUAL CXCR4-BTK INHIBITORS | X4 PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| WO-2023183652-A1 | DUAL CXCR4-BTK INHIBITORS | X4 PHARMACEUTICALS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| CN-113583007-B | Pyrrolopyrimidine BTK inhibitor and preparation method and application thereof | 山东大学 | 2022-06-10 | — | — | CN | disclosed |
| EP-4008328-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | AbbVie Inc. (US) | 2022-06-08 | — | — | EP | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| EP-3204382-B1 | HETEROARYL COMPOUNDS AS BTK INHIBITORS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2021-12-01 | — | — | EP | disclosed |
| CN-113583007-A | Pyrrolopyrimidine BTK inhibitor and preparation method and application thereof | 山东大学 | 2021-11-02 | — | — | CN | disclosed |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | ABBVIE INC. | 2021-06-17 | — | — | US | disclosed |
| US-10669238-B2 | Irreversible bruton's tyrosine kinase inhibitor | HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES (CN) | 2020-06-02 | — | — | US | disclosed |
| EP-3280419-B1 | INDAZOLE AND AZAINDAZOLE BTK INHIBITORS | MERCK SHARP & DOHME (US) | 2019-10-30 | — | — | EP | disclosed |
| EP-2068849-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI Pharmaceuticals, Inc. (US) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009053269-A1 | NOVEL KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-30 | — | — | WO | disclosed |
| US-20090105209-A1 | BTK protein kinase inhibitors | ROCHE PALO ALTO LLC | 2009-04-23 | — | — | US | disclosed |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | GILEAD CONNECTICUT, INC. | 2008-06-26 | — | — | US | disclosed |
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | GILEAD CONNECTICUT, INC. | 2008-06-12 | — | — | US | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033858-A2 | KINASE INHIBITORS, AND METHODS OF USING AND IDENTIFYING KINASE INHIBITORS | CGI PHARMACEUTICALS, INC. (US) | 2008-03-20 | — | — | WO | disclosed |
| EP-1863766-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | GILEAD CONNECTICUT, INC. | 2006-10-12 | — | — | US | disclosed |
| WO-2006099075-A2 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | CGI PHARMACEUTICALS, INC. (US) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139557-A1 | CERTAIN SUBSTITUTED AMIDES, METHOD OF MAKING, AND METHOD OF USE THEREOF | BTK, SYK, MYD88 | RAB9A 2778/4885NPC1 1118/4885SMN1; SMN2 3588/4885 |
| US-10669238-B2 | Irreversible bruton's tyrosine kinase inhibitor | BTK, ABL1, SYK | RAB9A 2595/4885NPC1 2247/4885SMN1; SMN2 1229/4885 |
| US-20210179556-A1 | PRIMARY CARBOXAMIDES AS BTK INHIBITORS | BTK, SYK, MYD88 | RAB9A 2208/4885NPC1 2919/4885SMN1; SMN2 4120/4885 |
| US-20090105209-A1 | BTK protein kinase inhibitors | BTK, SYK, LYN | RAB9A 1663/4885NPC1 4365/4885SMN1; SMN2 4495/4885 |
| US-20060229337-A1 | Certain substituted amides, method of making, and method of use thereof | BTK, SYK, MYD88 | RAB9A 3055/4885NPC1 1749/4885SMN1; SMN2 3454/4885 |
| US-20080153834-A1 | Certain Substituted Amides, Method of Making, and Method of Use Thereof | BTK, SYK, MYD88 | RAB9A 2778/4885NPC1 1118/4885SMN1; SMN2 3588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.